Top 40 Life Science Startup Investors in Denmark in November 2024
A list of 40 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Denmark. We rank investors based on the number of investments they made in Life science companies from Denmark. We update this investor list every month.Top 40 Life Science Startup Investors in Denmark in November 2024
Investor | Life Science Denmark investments |
---|---|
BioInnovation Institute | 4 |
Novo Holdings | 4 |
Northzone | 2 |
Sunstone Life Science Ventures | 2 |
VF Venture | 2 |
+ND Capital | 2 |
Balderton Capital | 2 |
People Ventures | 1 |
BlueYard Capital | 1 |
Nordic Alpha Partners | 1 |
Per Falholt | 1 |
Bioqube Ventures | 1 |
RA Capital Management | 1 |
Vaekstfonden | 1 |
SLS Venture | 1 |
Danske Bank | 1 |
Innovestor | 1 |
Seed Capital | 1 |
Verve Ventures | 1 |
Innovation Fund Denmark | 1 |
Amino Collective | 1 |
HealthCap | 1 |
Sound Bioventures | 1 |
p53 | 1 |
Ysios Capital | 1 |
LF Investment | 1 |
Nucleus Capital | 1 |
Vaekstfonden | 1 |
Industrifonden | 1 |
Swisscanto Private Equity | 1 |
Teknoinvest | 1 |
GGV Capital | 1 |
ATP | 1 |
David Helgason | 1 |
Biofund | 1 |
Seventure Partners | 1 |
Noble Resources | 1 |
PSV | 1 |
Nucleus Capital | 1 |
Steen Riisgaard | 1 |
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Convertible Note, Pre-Seed, Debt Financing
- Denmark, Germany, Switzerland
Portfolio highlights
- NorFalk — NorFalk rethinks the way to produce surfactants: the active and stabilizing ingredients in household care and personal care consumer products.
- ArcanaBio — ArcanaBio is developing realtime biosurveillance solutions that minimize workplace disruptions and support health & wellness
- HHC Medical — HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- AvenCell — Next generation immunotherapies for hard-to-treat cancers that are allogeneic and switchable.
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
- Booster Therapeutics — Booster Therapeutics is a biotech business that regulates cellular homeostasis and develops treatments for age-related disorders.
Northzone is a multi-stage venture capital fund that seeks to invest in the healthcare, semiconductors, software, hardware, artificial intelligence, blockchain, and gaming industries.
Show more
Investment focus
- Software, E-Commerce, FinTech
- Series A, Series B, Seed
- United States, Sweden, United Kingdom
Portfolio highlights
- TrueLayer — We power faster and safer online payments with our open banking payments network. Onboard users, accept payments & make payouts in seconds. Learn more today.
- AirForestry — AirForestry thins forests in a completely new way, namely from the air. #Re-inventing Forestry
- Yonder — A modern lifestyle credit card packed with rewards, no foreign exchange fees, and loads more. Apply without needing a UK credit score.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more
Investment focus
- Software, Biotechnology, SaaS
- Seed, Funding Round, Series A
- Denmark, United Kingdom, Iceland
Portfolio highlights
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Switzerland, Denmark
Portfolio highlights
- Vandria — At the vanguard of Mitochondrial research
- Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more
Investment focus
- Software, FinTech, Financial Services
- Series B, Series A, Series C
- United Kingdom, United States, Germany
Portfolio highlights
- Delli — We're a company just starting out on our mission to make good food accessible and enjoyed by all.
- Convergence — Convergence focuses on developing AI assistants to learn, adapt, and retain information to manage tasks effectively. Convergence provides Proxy, a personal AI agent to assist individuals with their unique administrative tasks in beta. The funding will be utilized to create innovative models that enhance Proxy assistants, surpassing the capabilitiesof the current generation of AI, emphasizing facilitating continuous learning and skill development through memory.
- Convergence Labs — Convergence Labs builds a future of abundance for all of humanity.
People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts.
Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.
Show more
Investment focus
- Health Care, Internet of Things, Software
- Seed, Pre-Seed, Series A
- Denmark, Sweden, United States
Portfolio highlights
- Uniify — Uniify is a no-code customer onboarding software that makes it fast, easy and secure for financial companies to onboard their customers. Save your business time and money, and build onboarding flows for your customers in minutes instead of months.
- proemial — Bridging minds, making research accessible. Personalized summaries connecting you to the latest scientific discoveries and the researchers behind them.
- Version Lens — Meet your new Product Management Co-Pilot. Reduce overhead for your product team so you can focus on what truly matters, building outstanding products.
BlueYard backs founders building the interconnected elements that can become the fabric of our future.
Show more
Investment focus
- Software, Biotechnology, Internet
- Seed, Series A, Funding Round
- United States, Germany, United Kingdom
Portfolio highlights
- CPTx — At CPTx, we develop new treatment paradigms across outsized medical challenges, with an initial focus on infectious diseases. The flexibility and precision of CPTx's platform supports multivalent drug development, which is crucial for addressing complex disease states involving multiple binding sites, such as viruses, cancer, and autoimmune diseases.
- Clock Bio — Clock Bio operates as a biotech company, that develops novel regenerative medicines.
- ExpressionEdits — Redefining the status quo of protein expression
Nordic Alpha Partners (NAP) is a growth fund founded in 2017. NAP target companies are typically locally or regionally established players with a revenue of DKK 10-150 mio. and with a global potential that can be fulfilled through new sustainable technologies such as energy storage and 3D print. The company is based in Hellerup, Denmark.We arelooking for:
• SME’s based in Northern Europe with 10-150 MDKK in turnover
• A proposition that either “enables” or “leverages” industrial, green or digital transformation.
• Ambitious teams, looking for capital and/or skills to fuel their growth journeyWe offer truly intelligent capital and partnership via:
• Our “hands on” fund management philosophy
• A vast “value creation framework” supporting rapid business acceleration
• Access to leaders and specialists within global Industry transformation
• A fund management team with extensive operational experience across startups, international business scaling, the industry/technology sector and corporate business
Show more
Investment focus
- Energy, Energy Storage, Renewable Energy
- Funding Round, Seed, Series A
- Denmark, Germany, Sweden
Portfolio highlights
- SunRoof — Roof of the future
- Mater Design — Founded in Copenhagen in 2006, Mater was created to be the pioneering global brand with sustainability embedded in its core. From the very beginning the ambition was to inspire a global design audience and engage people into sustainable thinking.
- Stabl Energy — Stabl Energy is a developer of a technology that significantly improves battery storage systems.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more
Investment focus
- Biotechnology, Robotics, Life Science
- Seed, Pre-Seed, Series A
- Denmark
Portfolio highlights
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
A life science venture capital fund - investing globally in exciting science to accelerate breakthrough therapies in patients.
Show more
Investment focus
- Biotechnology, Therapeutics, Life Science
- Seed, Series A, Series B
- United States, France, Denmark
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- Commit Biologics — Add a description for facebook
- SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Canada
Portfolio highlights
- Monopar — Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.Its lead compound, Hu-ATN-658, is a novel monoclonal antibody for the potential treatment of several deadly cancers. Hu-ATN-658 targets the urokinase plasminogen activator receptor (uPAR). Cancer Research UK will be conductingHu-ATN-658’s early development, including a Phase I clinical trial.In 2014, Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar founded the company in Wilmette, Illinois.
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more
Investment focus
- Software, Information Technology, SaaS
- Seed, Funding Round, Pre-Seed
- Denmark, United States, United Kingdom
Portfolio highlights
- Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
- Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
- kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
SLS Venture, a Scandinavian-based venture capital company, is the result of the merger of the life science team from The Sixth Swedish National Pension Fund, Medicon Valley Capital and Innoventus.
The fund is one of the largest investment funds in Scandinavia in the life science sector with approx. € 270 M (USD 325 M) under management.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series C, Funding Round, Series A
- Denmark, United States, Sweden
Portfolio highlights
- AdvanDx — I found a great domain name for sale on Dan.com. Check it out!
- OxThera — OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for thetreatment of primary hyperoxaluria.
- Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Danske Bank is a Nordic universal bank offering a full range of banking services. It was founded 5 October 1871 as Den Danske Landmandsbank, Hypothek- og Vexelbank i Kjøbenhavn (The Danish Farmers' Bank, Mortgage and Exchange Bank of Copenhagen). It is headquartered in Copenhagen, Denmark and is one of the major retail banks in the northernEuropean region with over 5 million retail customers.Danske Bank was number 454 on the Fortune Global 500 list for 2011.
Show more
Investment focus
- Biotechnology, Apps, Payments
- Funding Round, Post-IPO Debt, Debt Financing
- Denmark, Sweden, United States
Portfolio highlights
- FlexQube — FlexQube is a manufacturer and distributor of material handling equipment. They offer a flexible system of a few standard components that can be used to build industrial material handling applications. Their products are pallet carts, kit carts, and shelf carts.
- Rottneros — Rottneros manufactures paper pulp products. They offer mechanical pulp as well as bleached and unbleached chemical pulp. They also offer baking paper, wallpaper, packaging, air filters, electrical applications, datasheets, and laminate floors.
- Renewable Power Capital — Renewable Power Capital invest in the development, construction and long-term ownership of solar, onshore wind and battery storage projects.
Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.
Show more
Investment focus
- Software, Health Care, Manufacturing
- Seed, Funding Round, Series A
- Finland, Denmark, Sweden
Portfolio highlights
- Kausal — Kausal helps cities turn their climate goals into action through a digital platform that enables smarter collaboration around key data.
- Confidentialmind — The ConfidentialMind software stack enables you to integrate AI-solutions such as language models into your workflows and processes without data leaks to third parties. We will find a way to protect your data.
- Polku Therapeutics — Polku Therapeutics operates as a therapeutics company. Polku Therapeutics develops novel disease-halting therapies which provides new treatment options.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more
Investment focus
- Software, Health Care, SaaS
- Seed, Funding Round, Series A
- Denmark, United States, United Kingdom
Portfolio highlights
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
- Embla — Embla provides an online medical weight loss treatment using prescription drugs and coaching. The company provides patients with evidence-based treatments, digital tools, medication, and coaching to facilitate sustainable weight loss. Embla was founded in 2021 and is headquartered in Copenhagen, Denmark.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, Germany, France
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
- Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more
Investment focus
- Software, SaaS, Information Technology
- Grant, Pre-Seed, Seed
- Denmark, United States
Portfolio highlights
- Artelize — Discover events, performers and works within classical music, opera, musical, ballet & dance and drama. 252736 events, and 70641 artists and creators.
- Tryp.com — There is always a reason to go! We use artificial intelligence to find the best travel deals at the lowest price. The algorithm compares and connects flights, trains, and buses to create the perfect multidestination trips with matching hotel offers.
- Curvature AI — Grow your revenue with discounts and special offers selected and optimized by AI.
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Pre-Seed
- United States, Germany, United Kingdom
Portfolio highlights
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- ExpressionEdits — Redefining the status quo of protein expression
- Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Funding Round
- United States, Sweden, France
Portfolio highlights
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
- Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
- SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
Sound Bioventures is a venture capital fund investing in clinical stage companies.
Show more
Investment focus
- Medical, Biotechnology, Therapeutics
- Series A, Seed, Series B
- France, Denmark, United States
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
- AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
p53 identifies and invests in innovative healthcare companies, particularly in the fields of biotechnology and medical devices.
Show more
Investment focus
- Biotechnology, Medical, Life Science
- Series A
- Norway, Denmark
Portfolio highlights
- Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Spain, United States, Switzerland
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
- Engrail Therapeutics — Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
LF Investment is the investment arm of The Lauritzen Foundation, which is the parent company of the shipping companies J. Lauritzen (wholly-owned) and DFDS (42,8% holding). LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.
Show more
Investment focus
- Medical, Wellness, Health Care
- Funding Round
- Denmark
Portfolio highlights
- Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.
Supporting purpose-driven founders solving systemic challenges to planetary health.
Show more
Investment focus
- Biotechnology, Information Technology, Food and Beverage
- Pre-Seed, Seed, Series A
- Germany, United Kingdom, United States
Portfolio highlights
- Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
- Ucaneo — We Leveraging the magic of the human body to remove CO2 from the air.
- Izote Biosciences — Biomanufacturing Scale-Up Solution
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Funding Round, Pre-Seed
- Denmark, United States, Norway
Portfolio highlights
- Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
- Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
- kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Funding Round, Series A, Seed
- Sweden, United States, Denmark
Portfolio highlights
- Arevo — Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.
- Telness Tech — We help telcos maximize customer happiness and minimize OPEX through automation. Our proprietary, cloud-based, end-to-end BSS/OSS platform is connectivity ready in 64 countries.
- ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.
We invest in growth companies in the "late-stage venture/growth capital" phase, focussed on the technology and healthtech sectors.
Show more
Investment focus
- Health Care, Manufacturing, Robotics
- Series B, Series C, Funding Round
- Switzerland, Germany, Belgium
Portfolio highlights
- Fotokite — Specialized actively tethered UAS built for First Responders, providing immediate situational awareness of an emergency scene.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
- NIL Technology ApS — NIL Technology is an optical solutions company designing, developing, and manufacturing optical elements and components using high-precision nanoscale features
Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Funding Round, Series A
- Sweden, Norway, United States
Portfolio highlights
- GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.
We believe the talent to build great companies comes from anywhere. A global venture capital firm that invests in local founders. As a multi-stage, sector-focused firm, GGV focuses on seed- to growth-stage investments across Social/Internet, Enterprise Tech, and Smart Tech sectors.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Series B, Series A, Series C
- United States, China, Singapore
Portfolio highlights
- UXLINK — UXLINK is a social infrastructure comprised of social protocols and a collection of Dapps.UXLINk creates groundbreaking landing sceneries for web3 groups.
- Mind Network — The 1st Fully Homomorphic Encryption (FHE) Restaking Layer for AI and POS Networks. Mind Network is backed by Binance Labs, Hashkey, Big Brain, Chainlink, etc.
- Nozomi Networks — Nozomi Networks keeps operational technology cyber resilient with OT network and endpoint visibility, threat detection, and AI-powered analysis.
ATP is a self-governing institution, established by the Folketing by law in 1964. ATP's Board of Directors consists of equal representatives of employers and employees and an independent chairman of the board.
The ATP Group has approx. 3,000 employees. ATP is headquartered in Hillerød, customer service centers in Frederikshavn, Holstebro,Haderslev, Vordingborg, Lillerød and Hillerød, as well as offices in Copenhagen, Allerød and New York.
Show more
Investment focus
- Health Care, Health Diagnostics, Software
- Funding Round, Series B
- Denmark
Portfolio highlights
- DSV — Connect your business with the world: Global transport and logistics - road, air, sea, rail freight and warehousing. Contact us today.
- MedTrace Pharma — MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse.
- Visiopharm — Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robustsolution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras.Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis.Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.
David is a technologist, the founder of Unity Technologies, non-exec director to others, and a restless entrepreneur with a passion for creating feedback loops between innovation and teams and products, applying new and old business models to changing industries, and pushing people to do the very best they can do.David's background is inprogramming, an assortment of university dabbling, creating companies, and helping entrepreneurs. He served as CEO of Unity Technologies since co-founding it in 2003 and until October 2014, with an unflinching vision to democratize game development, and to develop technology and business models for the next phase of the games industry. David Helgason attended the University of Copenhagen.
Show more
Investment focus
- Software, Gaming, Information Technology
- Seed, Funding Round, Pre-Seed
- United States, Denmark, Finland
Portfolio highlights
- Isometric — Isometric is a carbon removal standard and registry.
- Slope — We handle the lending, underwriting, debt collection and fully pay out to you immediately once the product or service ships.
- Rocky Road — At Rocky Road, we are redefining social gaming with our social gaming network. We are hiring!
BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.
Show more
Investment focus
- Genetics, Medical, Health Care
- Funding Round, Seed
- Canada, Denmark, Russian Federation
Portfolio highlights
- Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
- RTM Diagnostika — Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer.
- Genizon BioSciences — Since 2005, we have helped thousands of people get the perfect domain name.
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Series B, Funding Round
- France, United States, Germany
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
- Sequentia Biotech — Sequentia Biotech is a bioinformatics company that offers services for healthcare, pharma, agriculture, industry and environment.
Noble Group is a global supply chain manager of energy, power & gas products, metals and carbon steel materials, with interests in key facilities that add value at various stages of its supply chains. Noble Group manages a diversified portfolio of essential natural resources, with integrated sourcing, marketing, processing, financing andtransportation operations. Noble Group's Energy segment encompasses a portfolio of oil liquids and coal products and continues to be a significant driver for the Group’s growth. Gas & Power segment includes their retail energy business Noble Americas Energy Solutions and Gas & Power wholesale operations. In Metals & Mining, Noble Group is one of the world’s leading suppliers with interests in iron ore, aluminium, special ores and alloys across key global locations. The Corporate segment incorporates the Logistics business as well as investments in their major associates. Noble Group (SGX: N21) manages a portfolio of global supply chains covering a range of industrial and energy products. Operating from over 60 locations, Noble facilitates the marketing, processing, financing and transportation of essential raw materials. Sourcing bulk commodities from low cost regions such as South America, South Africa, Australia and Indonesia, the Group supplies high growth demand markets, particularly in Asia and the Middle East. Noble Group is ranked number 77 in the 2015 Fortune Global 500. Noble moves essential resources from producers to consumer across the world. Noble Group's success relies on a rigorously managed balance sheet, effective partnerships and a deep understanding of customer needs. Noble’s core strategy is to be the best company in the world at moving the physical commodity from the producer to the consumer and managing the market, credit and operational risk associated with that. Noble Group's solid financial position comes from a rigorously managed balance sheet with exceptional liquidity and a carefully guided exposure to risk - underpinned by deep relationships with global capital providers. At Noble, they have forged some of the most productive and enterprising partnerships in the industry and they have always believed that as their partners grow, so do they. Noble Group put energy and focus into staying relevant and being valuable to their customers, keeping their interests firmly integrated into their DNA.
Show more
Investment focus
- Medical, Health Care, Genetics
- Funding Round
- Denmark, United Kingdom
Portfolio highlights
- Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
- Digital-Healthcare — Digital Healthcare is a health care company. The company has been acquired by EMIS Group.
PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.
Show more
Investment focus
- Software, Information Technology, SaaS
- Seed, Pre-Seed, Funding Round
- Denmark, United States, United Kingdom
Portfolio highlights
- spektr — spektr offers client onboarding, continuous compliance, and case management solutions that adapt to your business needs to automate your compliance processes.
- ZTLment — We empower online platforms and marketplaces to seamlessly hold, manage, and distribute funds in real-time, with full automation and compliance.
- Dynelectro — Dynelectro is a green energy technology company that focuses on reducing CO2 emissions by transforming fossil fuels into green fuels.
Supporting purpose-driven founders solving systemic challenges to planetary health.
Show more
Investment focus
- Biotechnology, Information Technology, Food and Beverage
- Pre-Seed, Seed, Series A
- Germany, United Kingdom, United States
Portfolio highlights
- Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
- Ucaneo — We Leveraging the magic of the human body to remove CO2 from the air.
- Izote Biosciences — Biomanufacturing Scale-Up Solution
Steen Riisgaard
Show more
Investment focus
- Life Science, Therapeutics, Biotechnology
- Pre-Seed
- Denmark
Portfolio highlights
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Investors by industry
Health Care
Google
Gaming
Climate
Energy
Community
Marketplace
Hardware
Biotech
Consumer
Proptech
Artificial intelligence
FinTech
Impact
EdTech
Sustainability
Venture Capital
Fashion
Big Data
Finance
Web3
B2B
Beauty
Retail
Education
Clean Energy
Oil and Gas
Food and Beverage
Real Estate
Video Games
Payments
Infrastructure
Photography
Financial Services
Organic Food
Publishing
Social Media
Social Network
Wellness
Enterprise Software
Medical
Android
Digital Media
Music
Legal
Franchise
Local
Internet
Construction
Sports
eSports
Manufacturing
Email
Mobile
Art
Hospitality
Biotechnology
Travel
Fitness
Recruiting
Platforms
Cannabis
Mobile Advertising
Medical Device
Automotive
Wine And Spirits
Crowdfunding
Social
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Theatre
Film
Life Science
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Germany
United Kingdom
India
Canada
South Korea
Australia
Ireland
New Zealand
United States
Africa
Vietnam
Saudi Arabia
Japan
South Africa
Europe
Oceania
LATAM
Indonesia
Middle East
Asia
Sri Lanka
China
Singapore
Brazil
Armenia
Qatar
Spain
Chile
Belgium
France
Belarus
Egypt
Ghana
Croatia
Ethiopia
Costa Rica
Kenya
Lithuania
Liechtenstein
Panama
Gibraltar
Myanmar
Lebanon
Cayman Islands
Mexico
Philippines
Greece
Mali
Norway
Malta
Israel
Italy
Kazakhstan
Cambodia
Peru
Kuwait
Malaysia
Nicaragua
Liberia
Mauritius
Morocco
Jersey
Slovenia
Thailand
Uzbekistan
Serbia
Zimbabwe
Sierra Leone
Zambia
Venezuela
Finland
Taiwan
Togo
Portugal
Turkey
Seychelles
San Marino
Uganda
Rwanda
Uruguay
Ukraine
Sweden
Senegal
Tanzania
Tunisia
Russian Federation
El Salvador
Poland
Puerto Rico
Tajikistan
Dominican Republic
Iraq
Bahamas
Azerbaijan
Belize
Nigeria
Iceland
Namibia
United Arab Emirates
Denmark
Honduras
Bolivia
Isle of Man
Luxembourg
Hong Kong
Pakistan
Albania
Barbados
Bahrain
Argentina
Jordan
Bangladesh
Grenada
Romania
Hungary
Georgia
Bermuda
Czech Republic
Ecuador
Bulgaria
Algeria
Estonia
Faroe Islands
Colombia
Oman
Cyprus
Latvia
Cameroon
Austria
Switzerland
Guatemala
Marshall Islands
Investors in Denmark by industry
Restaurants
Transportation
Social
Big Data
Education
Cryptocurrency
Finance
Payments
Food and Beverage
Mobile Apps
Medical
Financial Services
Medical Device
Sports
Fitness
Social Media
Internet
Manufacturing
Art
Music
Mobile
Blockchain
Legal
Software
Enterprise Software
eSports
Travel
Hospitality
Automotive
Platforms
Biotechnology
Recruiting
FinTech
Enterprise
Consumer
Health Care
Biotech
EdTech
Climate
Sustainability
Energy
Impact
Proptech
SaaS
Community
Hardware
Retail
Fashion
Beauty
B2B
Life Science
Sporting Goods
Photography
Renewable Energy
Wellness
Gaming
Real Estate
CleanTech
Construction
Non Profit
Web3
Marketplace
Artificial intelligence
Social Network
Media (entertainment)
Agriculture (agtech)
Social Impact
Video Games
Clean Energy